On October 23, 2026, a new publication involving MOTS-c appeared in the journal Biochemical Pharmacology. The study is titled "Mots-c attenuates diabetic nephropathy by downregulating LARS1 to promote lipophagy and suppress tubular senescence." This entry is listed under PubMed ID 42918312. MOTS-c remains classified as an unapproved compound used only in research settings. The publication record indicates the title, journal, and date as provided, without additional detail on study design or outcomes beyond what is stated in the title itself. No specific findings, data, or conclusions are summarized here beyond the title text. Readers interested in the full scope of the research should consult the original publication directly through the listed source. For broader context on MOTS-c, including its classification and general research background, readers can refer to the compound overview.
New Publication on MOTS-c in Diabetic Nephropathy Research
Source: https://pubmed.ncbi.nlm.nih.gov/42918312/